BioSpace News Archive

The development of the healthcare industry and the introduction of new drugs and therapeutics are the key factors estimated to encourage the growth of the global PEGylated proteins market in the next few years.

Company attracts three experienced industry executives to lead preclinical and clinical development as well as finance and operations

The Annual General Meeting of Nordic Nanovector ASA was held on 10 June 2020 in Oslo, Norway.

Fulcrum Therapeutics, Inc. announced the closing of a $68.5 million private placement pursuant to a securities purchase agreement with a group of institutional investors and accredited investors.

BiondVax Pharmaceuticals Ltd. announced the completion of the clinical study report of a Phase 2 clinical trial of the Company’s M-001 universal influenza vaccine candidate.

Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million Series C financing. Checkmate plans to use the proceeds from t

Otonomy, Inc. announced that due to the health, safety and travel concerns of stockholders and federal, state and local government recommendations and restrictions imposed in response to the novel coronavirus pandemic, the location of its 2020 Annual Meeting of Stockholders has changed.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personal

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside chat at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020 at 3:00 p.m. ET. A live webcast of the presentation will be available by visiting “Events and Presentations” in the In

Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Jean-Charles Soria, M.D., Ph.D., chief executive officer of Gustave Roussy Cancer Center, has joined the company’s scientific advisory board (SAB). “We are delighted that our co-founder Jean-Charles, a world-class medical oncologist and scientist, has r